Cushing's Syndrome Market

• The Cushing syndrome Market size is anticipated to grow in the coming years owing to the anticipated launch of potential candidates by key players like Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, and others developing their assets in the various stages of development. With the expected approval of all these therapies during the forecast period (2023–2032), the overall therapeutic market of Cushing Syndrome is likely to witness a rise at a significant CAGR.
• Other key factors propelling the Cushing Syndrome market include novel product launches and diagnostic solutions in the seven major markets. Launching emerging therapies based on novel techniques, such as HSD-1 inhibitors, ACTH antagonists, and others, is expected to fuel the Cushing Syndrome market and potentially reduce the market share of Steroidogenesis inhibitors, which are less effective and induce undesirable side effects.
• During the COVID-19 pandemic, there were disruptions in non-urgent medical services, including diagnostic tests and procedures. This led to delays in the diagnosis of Cushing’s syndrome and initiation of treatment. As a result, it affects the overall Cushing syndrome market.
• DelveInsight’s analyst estimated that the incidence of Cushing syndrome had increased in recent years. With a lack of late-stage pipeline products for Cushing syndrome, there is a likelihood for businesses to focus on revolutionary therapies with endpoints other than lowering cortisol levels in the body.

Download the Sample PDF to Get More Insight @ Cushing's Syndrome Market

DelveInsight’s report titled “Cushing Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” comprehensively analyzes Cushing Syndrome. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Cushing Syndrome segmented by gender and cause. The Cushing Syndrome market report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescription patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.

To gauge the market’s overall potential and identify business opportunities, the report discusses current Cushing Syndrome treatment practices and algorithms and unmet medical needs.

Cushing Syndrome Treatment Market

Cushing Syndrome Overview

Cushing’s syndrome, also known as hypercortisolism, is a rare hormonal disorder that occurs when the body is exposed to high cortisol levels for an extended period. Cortisol regulates various bodily functions, including metabolism, immune response, and stress response. However, when cortisol levels become chronically elevated, it leads to characteristic symptoms and complications.

Exogenous and endogenous factors cause Cushing’s syndrome. Exogenous Cushing Syndrome is the long-term use of corticosteroid medications in high doses or for extended periods, such as prednisone or increased glucocorticoid levels. Endogenous factors include the overproduction of cortisol by the adrenal glands and, in rare cases, by tumors in the body. Signs and symptoms of Cushing’s syndrome vary. People with very high cortisol levels for a long time will likely have clear signs of the disorder, including weight gain, thin arms and legs, a round face, increased fat around the base of the neck, easy bruising, and others.

Cushing Syndrome Diagnosis

Diagnosis of Cushing Syndrome is based on a high-dose dexamethasone suppression test (HDDST), midnight plasma cortisol, or corticotrophin-releasing hormone (CRH) stimulation test. Imaging studies, such as magnetic resonance imaging (MRI) of the pituitary gland, computed tomography (CT) scan of the adrenal glands, or other modalities, to locate the source of cortisol excess. In cases of Cushing’s disease, transsphenoidal surgery is the primary treatment option; adrenal tumors or hyperplasia may require adrenalectomy.

Cushing Syndrome Treatment Landscape

The treatment options for Cushing’s syndrome depend on the cause; if exogenous corticosteroids cause it, the dosage may be gradually reduced, or an alternative medication may be prescribed. Surgical removal and radiation may be recommended if a tumor is identified as the cause. In cases where surgery or radiation is not effective, medications may be prescribed to block cortisol production or inhibit its effects. ISTURISA (osilodrostat) is used to treat adults with Cushing’s disease who cannot have pituitary surgery, while NIZORAL (ketoconazole) primarily an antifungal medication, has been used off-label to inhibit cortisol synthesis in Cushing’s syndrome, KORLYM (mifepristone) and SIGNIFOR (pasireotide LAR) approved for the treatment of hyperglycemia associated with Cushing’s syndrome in patients who have type 2 diabetes and failed surgery or are not candidates for surgery.

While the immediate treatment is based on the stage of Cushing Syndrome progression, mifepristone, a glucocorticoid receptor antagonist, can rapidly improve the symptoms of Cushing’s syndrome, and bilateral adrenalectomy involves the surgical removal of both adrenal glands. This procedure can rapidly normalize cortisol levels and alleviate the symptoms of Cushing’s syndrome.

Cushing Syndrome Epidemiology

The Cushing Syndrome epidemiology section provides insights into the historical and current Cushing Syndrome patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

The epidemiology section of the Cushing Syndrome market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

Key Findings

• According to Nieman et al. (2015), the reported incidence of Cushing Syndrome was 6.2–7.6 per million person-years in the United States, which is expected to increase during the forecast period.
• According to Broersen et al. (2019), Cushing Syndrome is higher among women than men, with new cases diagnosed at a ratio of 3:1.

Cushing Syndrome Market Outlook

The global Cushing Syndrome market is expected to rise in the forecast period, with the main objective primarily focused on managing and treating the condition rather than seeking a complete cure. Various factors, including advancements in diagnosis and treatment, research and development activities, patient awareness, and healthcare policies, shape the market outlook for Cushing’s syndrome.

Over the years, the increase in the incidence of Crushing syndrome disease and the percentage of the aging population likely to suffer from this syndrome due to their weak immune system and poor lifestyle have all supported the Crushing syndrome market growth. The ongoing research and development efforts may result in the discovery of new treatment options or improvements in existing therapies. This could enhance the efficacy and safety profiles of medications, surgical techniques, and radiation therapy, leading to expanded patient treatment choices.

Additionally, Cushing’s syndrome can be challenging to diagnose correctly. The symptoms may overlap with other conditions, leading to underdiagnosis or misdiagnosis. Lack of awareness among healthcare professionals and limited access to specialized endocrine expertise can delay diagnosis and hinder market growth. The high cost of diagnostic tests, medications, surgeries, and follow-up care for Cushing’s syndrome can be difficult. If the tumor is the root of the problem, a full surgical removal is proposed and contributes to market share. Hospitals around the world have been investing heavily in the development of novel surgical treatments. Access to affordable healthcare, insurance coverage limitations, and financial constraints may limit patient access to optimal treatment, thus further affecting the overall market growth.

Addressing these challenges requires a multidisciplinary approach involving medical professionals, researchers, engineers, and specialists. The current treatment options for Cushing’s syndrome primarily aim to manage symptoms and normalize cortisol levels, but they may not provide a complete cure in all cases. The absence of curative therapies and the potential for disease recurrence can impact market growth and patient outcomes.

According to DelveInsight, the Cushing Syndrome market in the 7MM is expected to significantly change during the study period (2019–2032).

Cushing Syndrome Recent Developments

• On November 1, 2024, Corcept Therapeutics announced results from its Phase III GRADIENT trial for relacorilant, its investigational treatment for Cushing’s syndrome resulting from adrenal gland pathology.

Cushing Syndrome Drug Chapters

Cushing Syndrome Marketed Drugs

ISTURISA (osilodrostat): Novartis/Recordati

Osilodrostat is an orally active, nonsteroidal corticosteroid biosynthesis inhibitor developed by Novartis for treating Cushing’s syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing’s syndrome). In March 2020, the US FDA approved osilodrostat to treat endogenous Cushing’s syndrome in the United States. Osilodrostat received approval from the European Union in January 2020. Additionally, in March 2021, osilodrostat was licensed by the Japanese Ministry of Health, Labour, and Welfare (MHLW) to treat endogenous Cushing’s syndrome in patients for whom pituitary brain surgery has not been successful or is not an option.

Osilodrostat acts as a potent and selective aldosterone synthase inhibitor (CYP11B2) at higher dosages of 11β-hydroxylase (CYP11B1).

KORLYM (mifepristone): Corcept Therapeutics

In February 2012, mifepristone, developed by Corcept Therapeutics, was the first FDA-approved drug to treat endogenous Cushing’s syndrome. It is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s Syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Note: Detailed marketed therapies assessment will be provided in the final report....

Cushing Syndrome Emerging Drugs

The currently available treatments for Cushing Syndrome aim to mitigate the complications associated with the condition. The Cushing Syndrome market dynamics are expected to change primarily due to increased healthcare expenditures worldwide. Cushing Syndrome Market players such as Corcept Therapeutics, Recordati, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, and others are actively involved in developing treatments for Cushing Syndrome.

CRN04894: Crinetics Pharmaceuticals

CRN04894 is the first reported oral, selective adrenocorticotropic hormone (ACTH) antagonist that acts at the melanocortin 2 receptor (MC2R) for the treatment of Cushing’s disease and other diseases of excess ACTH, such as congenital adrenal hyperplasia. ACTH acts through the melanocortin type 2 receptor (MC2R) primarily expressed in the adrenal gland.

SPI-62: Sparrow Pharmaceuticals

SPI-62 is an oral small molecule, 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, designed to reduce intracellular cortisol levels and mitigate its numerous adverse effects. The HSD-1 inhibition may not share the undesirable effects of completely blocking the glucocorticoid receptor, lowering ACTH, or inhibiting multiple steroidogenic enzymes, as currently approved therapies do.

Note: Detailed emerging therapies assessment will be provided in the final report...

Cushing Syndrome Market Segmentation

DelveInsight’s ‘Cushing Syndrome Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future Cushing Syndrome market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Cushing Syndrome Market Size by Countries

The total Cushing syndrome market size is analyzed for individual countries (the United States Market, EU4 [Germany, France, Italy, and Spain] and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for Cushing Syndrome in 2022 due to the high prevalence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.

Cushing Syndrome Market Size by Therapies

To depict each nation’s distinct historical and projected market shares, the Cushing Syndrome market is separated by therapies and medication classes. Ongoing research focuses on strategies based on specific causes of Cushing’s syndrome, such as Cushing’s disease (pituitary-dependent), adrenal tumors, or ectopic ACTH syndrome. Medications such as ketoconazole, mifepristone, pasireotide, and metyrapone control cortisol levels and manage symptoms of Cushing’s syndrome. Transsphenoidal surgery, surgical removal of adrenal tumors or hyperplasia, is performed in cases of adrenal-dependent Cushing’s syndrome to enhance recovery and improve the quality of life for individuals suffering from Cushing Syndrome and its associated disease.

However, the cost of diagnosis and treatment for Cushing’s syndrome can be high, including specialized tests, surgeries, medications, and long-term monitoring. Limited access to healthcare services and insurance coverage may restrict patients’ ability to receive timely and appropriate treatment, affecting market growth.

Note: Detailed market segment assessment will be provided in the final report...

Cushing Syndrome Drugs Uptake

This section focuses on the sales uptake of potential Cushing Syndrome drugs that have recently launched or are anticipated to be launched in the Cushing Syndrome market between 2019 and 2032. It estimates the market penetration of the Cushing Syndrome drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Cushing Syndrome market.

The emerging Cushing Syndrome therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry, and other market dynamics and the unmet need they fulfill in the Cushing Syndrome market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Cushing Syndrome...

Cushing Syndrome Market Access and Reimbursement

DelveInsight’s ‘Cushing Syndrome Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of Cushing Syndrome.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Cushing Syndrome market trends and fill gaps in secondary findings, we interview KOLs and SMEs working in the Cushing Syndrome domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Cushing Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Cushing Syndrome unmet needs.

Cushing Syndrome: KOL Insights

• DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Nantes Université in France, the Department of Neurological Surgery at Duke University Medical Center, and Durham in the US.
• “Cushing syndrome is becoming more common as the number of patients with type 2 diabetes, high blood pressure, and poorly managed blood glucose levels are rising.”
• “Based on the stage of Cushing Syndrome progression, osilodrostat is recommended in adults who cannot undergo surgery.”

Note: Detailed assessment of KOL Views will be provided in the full report of Cushing Syndrome...

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Cushing Syndrome Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Cushing Syndrome Pipeline Development Activities

The report provides insights into Cushing Syndrome Clinical Trials within Phase II and Phase III stages. It also analyzes Cushing Syndrome Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging Cushing Syndrome therapies.

Cushing Syndrome Report Insights

• Cushing Syndrome Patient Population
• Cushing Syndrome Therapeutic Approaches
• Cushing Syndrome Pipeline Analysis
• Cushing Syndrome Market Size and Trends
• Cushing Syndrome Market Opportunities
• Impact of Upcoming Cushing Syndrome Therapies

Cushing Syndrome Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Cushing Syndrome Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Cushing Syndrome Market
• Cushing Syndrome Drugs Uptake

Cushing Syndrome Report Assessment

• Cushing Syndrome Current Treatment Practices
• Cushing Syndrome Unmet Needs
• Cushing Syndrome Pipeline Product Profiles
• Cushing Syndrome Market Attractiveness
• Cushing Syndrome Market Drivers
• Cushing Syndrome Market Barriers

Key Questions Answered In The Cushing Syndrome Market Report

• What are the key findings of the market across the 7MM, and what country will have the largest Cushing Syndrome market size during the forecast period (2023–2032)?
• What are the major causes of Cushing Syndrome, and how is it diagnosed?
• At what CAGR is the Cushing Syndrome market, and is epidemiology expected to grow in the 7MM during the forecast period (2023–2032)?
• How would the unmet needs impact the Cushing Syndrome market dynamics and subsequently influence the analysis of related trends?
• What would be the forecasted patient pool of Cushing Syndrome in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?
• What are the current treatment guidelines and options for Cushing Syndrome in the US, Europe, and Japan?
• What are the latest advancements in novel therapies, targets, mechanisms of action, and technologies being developed to address the limitations of existing therapies for Cushing Syndrome?
• How many companies are currently engaged in the development of therapies for the treatment of Cushing Syndrome?